Under the framework of the implementation of the Global Action Plan on Antimicrobial Resistance, WHO undertakes an annual quantitative and qualitative analysis of the clinical development pipeline of antibacterial treatments that target the WHO priority pathogens, TB and Clostridioides difficile. The role of the advisory group is to validate data gathered on the pipeline and to support WHO in the qualitative analysis.
The virtual meeting of the 4th Clinical Antibacterial Pipeline Advisory Group Meeting will take place 23 - 24 November 2020 to inform the update of the 2020 clinical antibacterial pipeline analysis.
Advisory Group Members
Cesar Arias, Professor, University of Texas Health Science Center, Houston, USA and Founder and Scientific Advisor Molecular Genetics and Antimicrobial Resistance Unit/International Center for Microbial Genomics, Universidad El Bosque, Colombia
Mark Butler, Senior Research Office, Institute for Molecular Bioscience, University of Queensland, Australia
Lloyd Czaplewski, Director, Chemical Biology Ventures Limited, UK
Francois Franceschi (Observer), Project Lead, Antimicrobial Member Recover and Exploratory Programme, Global Antibiotic R&D Partnership (GARDP), Switzerland
Prabha Fernandes, Chair of the Scientific Advisory Committee, GARDP, Switzerland
Stephan Harbarth, Head, Antimicrobial Stewardship Program, Geneva University Hospitals and Faculty of Medicine, Switzerland
Jennie Hood (Observer), Scientific Programme Officer, Global AMR R&D Hub, Germany
Roman Kozlov, Rector, Smolensk State Medical University, Russian Federation
Christian Lienhardt, Director of Research, Université de Montpellier, France
Norio Ohmagari, Director, National Center for Global Health and Medicine Hospital, Japan
Mical Paul, Head, Division of Infectious Diseases, Rambam Health Care Center, Israel
John Rex, Director, F2G, Ltd, USA
Mike Sharland (Observer), Chair, WHO Antibiotic Working Group of the EML/EMLc, and St George’s University London, UK
Lynn Silver, Director, LL Silver Consulting, USA
Melvin Spigelman, President and Chief Executive Officer, TB Alliance, USA
Guy Thwaites, Director, Oxford University Clinical Research Unit (OUCRU), Viet Nam
Declarations of Interests
The WHO Secretariat has received and assessed all of the DOIs submitted by the participating experts. In accordance with WHO's policy, all declared interests, even if they do not give rise to a conflict of interest that would warrant partial or total exclusion of the expert concerned, will be disclosed at the beginning of the meeting so that other members are aware of them.